Huntsman Cancer Institute (HCI) at the University of Utah is the first Regence provider designated as a national Blue Distinction Center for Cellular Immunotherapy.
Chimeric antigen receptor (CAR) T-cell therapy (CAR–T)-designated hospitals must be certified by a Risk Evaluation and Mitigation
Strategy program and must be accredited by the Foundation for Accreditation of Cellular Therapy, including according to Standards for Immune Effector Cells. HCI has also committed to systemwide monitoring and reporting of CAR T-cell patient outcomes through the Center for International Blood and Marrow Transplant Research registry.
Currently, there are no other CAR–T Cellular Immunotherapy Blue Distinction Centers elsewhere in Utah or in the surrounding states of Colorado, Wyoming, Idaho, Nevada, Arizona, or New Mexico. ■
